Home Cart Sign in  
Chemical Structure| 58749-23-8 Chemical Structure| 58749-23-8

Structure of Licochalcone B
CAS No.: 58749-23-8

Chemical Structure| 58749-23-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Licochalcone B, extracted from Glycyrrhiza uralensis, effectively inhibits the aggregation of amyloid-beta (Aβ42), showing anticancer properties.

Synonyms: Lico B

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Licochalcone B

CAS No. :58749-23-8
Formula : C16H14O5
M.W : 286.28
SMILES Code : O=C(C1=CC=C(O)C=C1)/C=C/C2=CC=C(O)C(O)=C2OC
Synonyms :
Lico B
MDL No. :MFCD20527294
InChI Key :DRDRYGIIYOPBBZ-XBXARRHUSA-N
Pubchem ID :5318999

Safety of Licochalcone B

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
THP-1 macrophages 10 μM 48 hours Evaluate the anti-inflammatory activity of Licochalcone B, showing significant inhibition of IL-1β P17 secretion in SFTSV-infected THP-1 macrophages. Proc Natl Acad Sci U S A. 2023 May 2;120(18):e2301775120
HaCaT 10, 20, 30 μM 48 hours LCB showed no significant toxicity to HaCaT cells. Antioxidants (Basel). 2023 Mar 7;12(3):656
JB6 10, 20, 30 μM 48 hours LCB showed no significant toxicity to JB6 cells. Antioxidants (Basel). 2023 Mar 7;12(3):656
Calu-3 cells 1.1, 3.3, 10, 30 μM 48 hours Evaluate the inhibitory effect of Licochalcone B on SARS-CoV-2-induced inflammatory responses, showing dose-dependent reduction of IL-1β P17 release. Proc Natl Acad Sci U S A. 2023 May 2;120(18):e2301775120
human liver microsomes 14.07 ± 1.55 μM 3 min or 33 min preincubation To evaluate the inhibitory effect of Licochalcone B on human CYP3A, results showed that Licochalcone B inhibited CYP3A in a time-dependent manner, with IC50 values decreasing from 14.07 μM to 6.81 μM. Acta Pharmacol Sin. 2022 Apr;43(4):1072-1081
A549 cells 139.70 μM 1 hour Evaluate the activity of Licochalcone B as a B2 receptor antagonist, results showed significant antagonist activity. J Ethnopharmacol. 2021 Nov 15;280:114488
HT-29 cells 25.12 μM 1 hour Evaluate the activity of Licochalcone B as a GPR35 agonist, results showed significant agonist activity. J Ethnopharmacol. 2021 Nov 15;280:114488
HCT116-OxR 10, 20, 30 μM 24 or 48 hours LCB significantly inhibited the viability of HCT116-OxR cells with an IC50 value of 26.86 μM. Antioxidants (Basel). 2023 Mar 7;12(3):656
HCT116 10, 20, 30 μM 24 or 48 hours LCB significantly inhibited the viability of HCT116 cells with an IC50 value of 25.21 μM. Antioxidants (Basel). 2023 Mar 7;12(3):656
human peripheral blood mononuclear cells (hPBMCs) 20 μM 1 hour To evaluate the effect of LicoB on NLRP3 inflammasome activation in hPBMCs, results showed inhibition of IL-1β secretion and caspase-1 cleavage EMBO Rep. 2022 Feb 3;23(2):e53499
PMA-differentiated THP-1 cells 20 μM 1 hour To evaluate the effect of LicoB on NLRP3 inflammasome activation in THP-1 cells, results showed inhibition of IL-1β secretion and caspase-1 cleavage EMBO Rep. 2022 Feb 3;23(2):e53499
mouse bone marrow-derived macrophages (BMDMs) 0-80 μM 24 hours To evaluate the cytotoxicity of LicoB on BMDMs, results showed no cytotoxicity below 80 μM EMBO Rep. 2022 Feb 3;23(2):e53499
Human Pulmonary Microvascular Endothelial Cells (HPMECs) 400 ng/mL 48 hours Evaluate the protective effect of LCB against LPS-induced oxidative stress. LCB pretreatment significantly reduced LPS-induced ROS levels. Redox Rep. 2023 Dec;28(1):2243423
Human Pulmonary Microvascular Endothelial Cells (HPMECs) 0.1-0.7 μM 24 hours and 48 hours Evaluate the effect of LCB on cell viability and cytotoxicity in HPMECs. LCB significantly increased cell viability at concentrations of 0.1-0.7 μM, with the best effect at 400 nM. Redox Rep. 2023 Dec;28(1):2243423
RAW264.7 cells 0.25, 0.5, 0.75 µM 24 hours LCB alleviates BDE-47-induced apoptosis and oxidative stress in RAW264.7 cells by activating the Nrf2 pathway and inhibiting the NF-κB pathway. Antioxidants (Basel). 2024 Apr 10;13(4):445

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice LPS-induced septic shock model Intraperitoneal injection 20 or 40 mg/kg Single dose, monitored for 72 hours To evaluate the protective effect of LicoB on LPS-induced septic shock, results showed dose-dependent improvement in mouse survival EMBO Rep. 2022 Feb 3;23(2):e53499
C57BL/6 male mice LPS-induced acute lung injury model Intraperitoneal injection 10 mg/kg, 20 mg/kg, 40 mg/kg Once daily for seven consecutive days Evaluate the protective effect of LCB against LPS-induced acute lung injury. LCB significantly reduced pulmonary edema and oxidative stress markers and improved inflammatory responses. Redox Rep. 2023 Dec;28(1):2243423
Mice DOX-induced AKI model Intraperitoneal injection 200 μM 10 minutes incubation Licochalcone B was identified as a potential inhibitor of PAI-1, inhibiting its activity by direct binding. Chin Med. 2024 Nov 1;19(1):152

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.49mL

0.70mL

0.35mL

17.47mL

3.49mL

1.75mL

34.93mL

6.99mL

3.49mL

 

Historical Records

Categories